Edition:
Deutschland

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

52.36USD
22 Sep 2020
Change (% chg)

$-0.01 (-0.02%)
Prev Close
$52.37
Open
$52.36
Day's High
$52.45
Day's Low
$52.35
Volume
674,634
Avg. Vol
599,746
52-wk High
$52.45
52-wk Low
$12.24

About

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20... (more)

Buy/Sell

Sell Hold Buy
2.80 Mean rating from 10 analysts

Overall

Beta: 1.76
Market Cap(Mil.): $987.19
Shares Outstanding(Mil.): 76.23
Dividend: --
Yield (%): --

US STOCKS-S&P 500, Nasdaq hit record highs as Apple crosses $2 trillion mark

* S&P 500 touches all-time high for second consecutive session

Photo

J&J strikes $6.5 billion deal for autoimmune disease specialist Momenta

Johnson & Johnson agreed to buy Momenta Pharmaceuticals Inc for about $6.5 billion (4.9 billion pounds) on Wednesday, to bolster its portfolio of drugs for hard-to-treat autoimmune diseases.

UPDATE 4-J&J strikes $6.5 bln deal for autoimmune disease specialist Momenta

Aug 19 Johnson & Johnson agreed to buy Momenta Pharmaceuticals Inc for about $6.5 billion on Wednesday, to bolster its portfolio of drugs for hard-to-treat autoimmune diseases.

US STOCKS-S&P 500, Nasdaq hit record highs as Apple tops $2 trillion in market value

* Indexes up: Dow 0.35%, S&P 0.20%, Nasdaq 0.14% (Adds quote, details; updates prices)

US STOCKS-S&P 500 notches record high for second day after Target, Lowe's results beat

* Indexes: Dow rises 0.36%, S&P up 0.14%, Nasdaq dips 0.08% (Updates to market open)

US STOCKS-Wall St set to open higher after solid results from Lowe's, Target

* Futures: Dow up 0.13%, S&P up 0.08%, Nasdaq down 0.18% (Adds quote, updates prices)

Johnson & Johnson to buy Momenta for about $6.5 bln

Aug 19 Johnson & Johnson said on Wednesday it would buy Momenta Pharmaceuticals Inc for about $6.5 billion in cash to expand into the area of autoimmune disease treatments.

BRIEF-Momenta Announces Positive Topline Data From Interim Analysis Of Phase 2 Vivacity-MG Study Of Nipocalimab (M281)

* MOMENTA PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE DATA FROM INTERIM ANALYSIS OF PHASE 2 VIVACITY-MG STUDY OF NIPOCALIMAB (M281) IN GENERALIZED MYASTHENIA GRAVIS (GMG)

BRIEF-Momenta Pharmaceuticals Q1 Loss Per Share $0.34

* MOMENTA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL AND OPERATING RESULTS

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.21%
Rohstoffe -0.04%
Industrie -0.10%
Konjunktur abhängige Waren & Dienstleistungen -0.03%
Konjunktur unabhängige Waren & Dienstleistungen -0.16%
Finanzindustrie -0.06%
Pharma +0.00%
Technologie -0.35%
Telekommunikation -0.05%